The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies

Klinische Padiatrie

Volumn 216, Issue 3, 2004, Pages 150-156

  Korholz D ^a   Claviez, A ^d   Hasenclever, D ^a   Kluge, R ^a   Hirsch, W ^a   Kamprad, F ^a   Dorffel W ^c   Wickmann, L ^c   Papsdorf, K ^a   Dieckmann, K ^b   Kahn, T ^b   Mauz Korholz C ^a   Dannenberg, C ^a   Potter R ^b   Brosteanu, O ^a   Schellong, G ^e   Sabri, O ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Children; Dacarbazine; FDG PET radiotherapy; GPOH; Hodgkin's disease

Indexed keywords

ALKYLATING AGENT; ANTIINFECTIVE AGENT; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; ETOPOSIDE; METHOTREXATE; PROCARBAZINE;

AZOOSPERMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; EARLY MENOPAUSE; HODGKIN DISEASE; HUMAN; MALE STERILITY; OVARY INSUFFICIENCY; POSITRON EMISSION TOMOGRAPHY; RADIATION HAZARD; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; GERMANY; HODGKIN DISEASE; HUMANS; MULTICENTER STUDIES; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2942724673     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822627     Document Type: Review

References (43)

1. Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Widland M, Leverger G, Talbot JN. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002; 29: 1155-1165
2. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279
3. 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-25
4. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann CA, Schirrmeister H, Reske SN. 2-(fluorine-18)Fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. Cancer 2001; 91: 889-899
5. Dieckmann K, Potter R, Wagner W, Prott FJ, Hörnig-Franz I, Rath B, Schellong G. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Radiother Oncol 2002; 62: 191-200
6. Stumpe KDM, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-728
7. Lang O, Bihl H, Hültenschmidt B, Sautter-Bihl ML. Clinical relevance of positron emission tomography in treatment control and relapse of Hodgkin's disease. Strahlenther und Onkol 2001; 177: 138-144
8. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18-FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37
9. 18F fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934
10. 18F fluorodeoxyglucose after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Brit J Hematol 2001; 115: 272-278
11. Naumann R, Vaić A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Brit J Haematol 2001; 115: 793-800
12. 18FDG-PET and CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncology reports 2001; 8: 1393-1399
13. Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O. Importance of F18-Fluorodeoxy-D-2-Glucose positron Emission Tomography (FDG-PET) for Staging and Therapy Control of Hodgkin's Lymphoma in childhood and adolescence - Consequences for the GPOH-HD 2003 protocol. Onkologie 2003; 26: 489-493
14. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-751
15. Bhatia S, Yasui Y, Robinson LL, Birch JM, Bogue MK, Diller L, DeLa C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT. Late effekt Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report of the late effects study group. J Clin Oncol 2003; 21: 4386-4394
16. Schellong G, Waubke-Landwehr AK, Langermann HJ, Riehm HJ, Brämswig J, Ritter J. Prediction of splenic involvement in children with Hodgkin's disease. Significance of clinical and intraoperative findings. A retrospective statistical analysis of 154 patients in the German therapy study DAL-HD-78. Cancer 1986; 57: 2049-2056
17. Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze EW, Wickmann L. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Pädiatr 2003; 215: 139-145
18. Schellong G, Brämswig J, Ludwig R, Gerein V, Jobke A, Jürgens H, Kabisch H, Stollmann B, Weinel P, Gadner H et al. [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82]. Klin Pädiatr 1986; 198: 137-146
19. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K Children's Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771
20. Wickmann L, Lüders H, Dörffel W. 18-FDG-PET findings in children and adolescents ith Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and the predictive value of follow-up examinations. Klin Pädiatr 2003; 215: 146-150
21. Young H, Baum R, Cremerius U, Herholz K, Hoeckstra O, Lammertsma AA, Pruim J, Price P for the European Organization for research and Treatment of Cancer (EORTC) PET Study Group. Measurement of clinical and subclinical tumour response unsing 18-F-Fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35: 1773-1782
22. Dörffel W, Lüders H, Marciniak H, Parwaresch R, Schwarze EW, Wickmann L, Rühl U. Results of the multicenter trial GPOH-HD 95 for treatment of Hodgkin's disease in children and adolescents. Monatsschr Kinderheilkd 2002; 150: 1294
23. Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, Gaitini D, Kolodny GM, Israel O. Hodgkin disease: Prediction of outcome with 67 Ga scintigraphy after one cycle of chemotherapy. Radiology 1999; 210: 487-491
24. Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Bull U. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin 2001; 40: 23-30
25. Kostakoǧlu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027
26. Schellong G, Hörnig I, Brämswig J, Bökkerink JPM, Steinhoff A, Ludwig R, Niethammer D, Reiter A, Lengerke J, v Heinecke H, Schwarze EW, Pötter R, Müller RP, Wannenmacher M. Zur Bedeutung des Procarbazins in der Chemotherapie des Morbus Hodgkin - Ein Bericht der kooperativen Therapiestudie DAL-HD-85. Klin Pädiatr 1988; 200: 205-213
27. Brämswig JH, Heimes U, Heiermann E, Schlegel W, Nieschlag E, Schellong G. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 1990; 65: 1298-1302
28. Hassel JU, Bramswig JH, Schlegel W, Schellong G. [Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study]. Klin Pädiatr 1991; 203: 268-272
29. Schellong G, Bramswig JH, Hornig-Franz I, Schwarze EW, Potter R, Wannenmacher M. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group. Ann Oncol 1994; 5 (Suppl 2): 113-115
30. Schellong G, Potter R, Brämswig J, Wagner W, Prott FJ, Dorffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze EW The German-Austrian Pediatric Hodgkin's Disease Study Group. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. J Clin Oncol 1999; 17: 3736-3744
31. Gerres L, Bramswig JH, Schlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer 1998; 83: 2217-2222
32. Schellong G, Riepenhausen M. Spätfolgen nach Morbus Hodkin bei Kindern und Jugendlichen: ergebnisse der Studien DAL-HD 78-HD 90. Projektbericht 2002
33. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, Holmes GF, Holmes FF, Latourette HB, Meigs JW et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992; 166: 788-793
34. Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol 1987; 113: 260-266
35. rd, Luce JK, Talley RW, Vaitkevicius VK, Wilson HE. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. Cancer Chemother Rep 1972; 56: 667-670
36. Klener P, Donner L. Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Acta haemat 1977; 57: 272-278
37. Schellong G, Hörnig-Franz I. Salvage therapy results in childhood Hodgkin's disease. In: Zander AR, Barlogie B (eds). Autologous bone marrow transplantation for Hodgkin's lymphoma and multiple myeloma. Springer, Berlin, Heidelberg 1993; 8-10
38. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071
39. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC, Vose JM, Armitage JO, Coccia PF, Bierman PJ. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17: 825-831
40. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A, Meloni G. Autologous bone marrow transplantation for pediatric Hodgkin's disease: A case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993; 11: 2243-2249
41. Schmitz N, Glass B, Dreger P, Haferlach T, Horst HA, Ollech-Chwoyka J, Suttorp M, Gassmann W, Loffler H. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 1993; 66: 251-256
42. Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Potzi C, Raderer M, Dudczak R, Kletter K. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16: 260-267
43. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Diehl V, Engert A Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628-1635